{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Evaluating&page=2", "query": { "condition": "Evaluating", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Evaluating&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T17:10:01.111Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06645886", "title": "A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematologic Malignancies", "Adult" ], "interventions": [ { "name": "KQB198", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kumquat Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2024-12-09", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 10, "location_summary": "San Francisco, California • Denver, Colorado • Tampa, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06645886" }, { "nct_id": "NCT01009073", "title": "A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ABT-263", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" }, { "name": "irinotecan (3-week schedule)", "type": "DRUG" }, { "name": "irinotecan (weekly schedule)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 51, "start_date": "2009-10", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 4, "location_summary": "Santa Monica, California • Detroit, Michigan • San Antonio, Texas + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01009073" }, { "nct_id": "NCT01288469", "title": "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo (for atorvastatin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 92, "start_date": "2011-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2015-09-24", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 20, "location_summary": "Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Doral", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01288469" }, { "nct_id": "NCT05259566", "title": "Potential Impact of Menthol Ban in Cigarettes and E-cigarettes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Tobacco Smoking" ], "interventions": [ { "name": "menthol ban in cigarettes only", "type": "BEHAVIORAL" }, { "name": "total menthol ban", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 151, "start_date": "2022-12-01", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259566" }, { "nct_id": "NCT04575402", "title": "Digitally Captured Activity Data and PROs to Monitor Physical Function in Prostate Cancer Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Wearable Activity Monitor", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2021-02-19", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04575402" }, { "nct_id": "NCT03052231", "title": "Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Medication Adherence", "Cystic Fibrosis" ], "interventions": [ { "name": "caremessage", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Landon Pediatric Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 80, "start_date": "2016-03", "completion_date": "2017-02", "has_results": false, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03052231" }, { "nct_id": "NCT04169802", "title": "Study Evaluating Retinal Health Monitoring System Visual Acuity Module.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Age Related Macular Degeneration" ], "interventions": [ { "name": "Retinal Health Monitoring System Visual Acuity Module", "type": "DIAGNOSTIC_TEST" }, { "name": "Sloan letter, logarithmic near visual acuity chart (Reference Chart)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Kubota Vision Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 25, "start_date": "2019-11-20", "completion_date": "2020-04-15", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04169802" }, { "nct_id": "NCT00741819", "title": "Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "Inhaled treprostinil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 73, "start_date": "2008-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 15, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "New Hyde Park", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00741819" }, { "nct_id": "NCT07361731", "title": "Evaluating the Feasibility, Acceptability, and Preliminary Outcomes of Heart Rate Variability Biofeedback for Individuals With Opioid Use Disorder.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Autonomic Nervous System Imbalance", "Heart Rate Variability (HRV)", "Opioid Use Disorder", "Breathing Techniques", "Opioid Craving", "Recovery", "Emotional Regulation", "Positive and Negative Affect", "Stress", "Biofeedback" ], "interventions": [ { "name": "Heart rate variability biofeedback", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Arizona State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2025-12-01", "completion_date": "2026-02-01", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07361731" }, { "nct_id": "NCT06995677", "title": "Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low-grade NMIBC", "FGFR Gene Amplification", "FGFR Gene Alterations", "FGFR3 Gene Alteration", "FGFR3 Gene Mutation", "FGFR3 Gene Fusions" ], "interventions": [ { "name": "TYRA-300 60mg", "type": "DRUG" }, { "name": "TYRA-300 50mg", "type": "DRUG" }, { "name": "TYRA-300 Dose TBD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-06-27", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-25T17:10:01.111Z", "location_count": 30, "location_summary": "Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 27 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Murrieta", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06995677" } ] }